Search Articles — Sudonull

https://sudonull.com/t-technologies-open-source-strategy-in-ai-ml-and-llm-development

How the T-Technologies Group develops open source ecosystems in AI/ML, creating LLMs (T-Pro 2.0, T-One) and tools (Turbo Alignment), as well as investing in research and the community.

https://sudonull.com/t-tops-managing-project-uncertainty-after-release-it-practice

How the T-TOPS methodology helps separate management contours after product launch. Principles of parallel segmentation for Agile projects. Read the guide.

https://sudonull.com/why-developers-don-t-trust-ai-content-and-code

Study of the reasons for rejection of AI-generated content and code among IT specialists: psychology, information theory, and practical detection markers.

https://sudonull.com/ai-won-t-replace-it-specialists-9-facts

Learn why AI won't take jobs from developers: failed forecasts, low ROI, model errors. Facts and data for middle/senior IT. Adapt skills to reality.

https://sudonull.com/code-economy-rust-doesn-t-pay-off-in-projects

Breakdown of why switching to memory-safe languages doesn't reduce development costs. Software Economic Model: TCO, bug fixes, payback. For middle/senior dev. Read the analysis.

https://ymaho.com/heat-in-britain-air-conditioning-becomes-royal-luxury

Anomalous heat +38°C in London. Air conditioner caused police and memes. Why do Brits consider AC a luxury and electricity can't handle it? Read.

https://ymaho.com/t-beauty-in-taiwan-ai-skin-diagnostics-and-expansion

Thailand brings T-Beauty to Taiwan through AI skin analysis and cellular restoration. Learn how data strategy is changing the Asian market. Read the analysis.

https://ymaho.com/dual-action-car-t-100-remission-in-myeloma-at-isct-2026

ISCT 2026 data analysis: CAR-T therapy TPST-2003 showed complete response in all naive patients. Learn why this is a breakthrough, not an illusion, and what risks are hidden.

https://ymaho.com/car-t-therapy-hiv-years-of-remission-after-infusion

DUET-2 data: CAR-T cells keep HIV in remission for over 2 years without ART. Functional cure already a reality? Learn about the breakthrough in HIV treatment.

https://ymaho.com/car-t-therapy-for-ovarian-cancer-lira-cel-and-28-months-of-life

Updated Phase I data: CAR-T lira-cel showed 28-month survival in ovarian cancer. Learn why this is a breakthrough in solid tumor treatment.

https://ymaho.com/next-generation-car-t-tumor-neurobiology-and-brain-cancer-treatment

Scientists propose considering neurotransmitters for CAR-T cells in glioblastoma. A new approach to brain cancer therapy. Learn more.

https://ymaho.com/car-t-therapy-for-lupus-fda-approval-2026

Analysis of FDA approval of the first CAR-T cell therapy for severe lupus. Key players, forecasts, and hidden risks. Find out who is leading the race.

https://ymaho.com/universal-car-t-therapy-fda-allows-trials-for-autoimmune-diseases

FDA approved clinical trials of allogeneic CAR-T cell therapy QT-019C for lupus and scleroderma. Savings up to $100 billion, no chemotherapy. Learn about the breakthrough.

https://ymaho.com/car-t-therapy-against-aging-elimination-of-senescent-cells

An international consortium has developed CAR-T for selective elimination of senescent cells. Learn how uPAR CAR-T technology fights age-related diseases and fibrosis.

https://ymaho.com/car-t-therapy-for-lupus-100-remission-in-a-small-cohort

German rheumatologists achieved 100% remission in lupus with CAR-T. Four-year data, immune reset mechanism, and forecasts. Read.